- Home
- PROK vs CD Comparison
PROK vs CD Comparison
Compare PROK & CD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PROK | CD |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 417.1M | 352.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PROK | CD |
|---|---|---|
| Price | $2.48 | $4.80 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $7.40 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 230.5K |
| Earning Date | 11-10-2025 | 08-31-2023 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $744,000.00 | ★ $956,830.00 |
| Revenue This Year | $956.51 | $949,544.10 |
| Revenue Next Year | N/A | $14.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 33.48 |
| 52 Week Low | $0.46 | $1.38 |
| 52 Week High | $7.13 | $36.77 |
Technical Indicators
Market Signals| Indicator | PROK | CD |
|---|---|---|
| Relative Strength Index (RSI) | 54.72 | N/A |
| Support Level | $2.10 | N/A |
| Resistance Level | $2.29 | N/A |
| Average True Range (ATR) | 0.17 | 0.00 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 76.53 | 0.00 |
Price Performance
Historical ComparisonAbout PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About CD Chaince Digital Holdings Inc. Ordinary Shares
Chaince Digital Holdings Inc is digital fintech company providing access to the growing AI-powered infrastructure, blockchain, and digital assets. Its three core business lines include: blockchain and digital asset solutions, AI and HPC infrastructure, developing liquid cooling solutions for AI data centers and comprehensive financial services through Chaince Securities,LLC a FINRA-registered broker-dealer, and RIA.